{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T06:33:29Z","timestamp":1682058809414},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["MMW - Fortschritte der Medizin"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s15006-023-2446-6","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T23:01:57Z","timestamp":1682031717000},"page":"34-41","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diabetes und Nephropathie gemeinsam anpacken","Tackling diabetes and nephropathy together"],"prefix":"10.1007","volume":"165","author":[{"given":"Robin","family":"Sch\u00fcrfeld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"2446_CR5947","doi-asserted-by":"crossref","unstructured":"Otto T et al. Age-dependent prevalence of type 2 diabetes, cardiovascular risk profiles and use of diabetes drugs in Germany using health claims data. Diabetes Obes Metab 2022; 25 (3): 767-775","DOI":"10.1111\/dom.14924"},{"key":"2446_CR5953","doi-asserted-by":"crossref","unstructured":"Webster AC et al. Chronic Kidney Disease. Lancet 2017; 389 (10075): 1238-1252","DOI":"10.1016\/S0140-6736(16)32064-5"},{"key":"2446_CR5957","doi-asserted-by":"crossref","unstructured":"Thomas MC et al. Diabetic kidney disease. Nat Rev Dis Primers 2015; 1: 15018","DOI":"10.1038\/nrdp.2015.18"},{"key":"2446_CR5961","doi-asserted-by":"crossref","unstructured":"Merker L et al. Nephropathie bei Diabetes. Diabetologie 2022; 17 (3): S327-S331","DOI":"10.1055\/a-1908-0801"},{"key":"2446_CR5965","doi-asserted-by":"crossref","unstructured":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2022; 102 (5S):  S1-S127","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"2446_CR5973","doi-asserted-by":"crossref","unstructured":"Jiang S et al. Protein restriction for diabetic kidney disease. Cochrane Database Syst Rev 2023; 1 (1): CD014906","DOI":"10.1002\/14651858.CD014906.pub2"},{"key":"2446_CR5979","doi-asserted-by":"crossref","unstructured":"Mozaffarian D et al. Global sodium consumption and death from cardiovascular causes. N Engl J Med 2014; 371 (7): 624-634","DOI":"10.1056\/NEJMoa1304127"},{"key":"2446_CR5985","doi-asserted-by":"crossref","unstructured":"Clyne N, Anding-Rost K. Exercise training in chronic kidney disease-effects, expectations and adherence. Clin Kidney J 2021; 14(Suppl 2): 3-14","DOI":"10.1093\/ckj\/sfab012"},{"key":"2446_CR5995","doi-asserted-by":"crossref","unstructured":"Strippoli, G.F., et al., Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev, 2006. 2006(4): p. CD006257.","DOI":"10.1002\/14651858.CD006257"},{"key":"2446_CR5999","doi-asserted-by":"crossref","unstructured":"Williams B et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. J Hypertens 2018; 36 (10): 1953-2041","DOI":"10.1097\/HJH.0000000000001940"},{"key":"2446_CR6005","doi-asserted-by":"crossref","unstructured":"Group SR et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 373 (22): 2103-16","DOI":"10.1056\/NEJMoa1511939"},{"key":"2446_CR6009","doi-asserted-by":"crossref","unstructured":"Mach F et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41 (1): 111-88","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"2446_CR6017","doi-asserted-by":"crossref","unstructured":"Ebert T et al. Inflammation and Oxidative Stress in Chronic Kidney Disease and Dialysis Patients. Antioxid Redox Signal 2021; 35 (17): 1426-48","DOI":"10.1089\/ars.2020.8184"},{"key":"2446_CR6029","doi-asserted-by":"crossref","unstructured":"Flory J, Lipska K. Metformin in 2019. JAMA 2019; 321 (19): 1926-7","DOI":"10.1001\/jama.2019.3805"},{"key":"2446_CR6036","doi-asserted-by":"crossref","unstructured":"Turner R et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352 (9131): 854-65","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"2446_CR6042","doi-asserted-by":"crossref","unstructured":"Zelniker TA et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393 (10166): 31-9","DOI":"10.1016\/S0140-6736(18)32590-X"},{"key":"2446_CR6046","unstructured":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 2022; 400 (10365): 1788-801"},{"key":"2446_CR6053","doi-asserted-by":"crossref","unstructured":"Kristensen SL et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019; 7 (10): 776-85","DOI":"10.1016\/S2213-8587(19)30249-9"},{"key":"2446_CR6059","doi-asserted-by":"crossref","unstructured":"Scirica BM et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369 (14): 1317-26","DOI":"10.1056\/NEJMoa1307684"},{"key":"2446_CR6065","doi-asserted-by":"crossref","unstructured":"Bakris GL et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383 (23): 2219-29","DOI":"10.1056\/NEJMoa2025845"}],"container-title":["MMW - Fortschritte der Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15006-023-2446-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15006-023-2446-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15006-023-2446-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T23:05:14Z","timestamp":1682031914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.springermedizin.de\/doi\/10.1007\/s15006-023-2446-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["2446"],"URL":"https:\/\/doi.org\/10.1007\/s15006-023-2446-6","relation":{},"ISSN":["1438-3276","1613-3560"],"issn-type":[{"value":"1438-3276","type":"print"},{"value":"1613-3560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"21 April 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Die Autorrn erkl\u00e4ren, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten lie\u00dfen. Sie legen folgende potenzielle Interessenkonflikte offen: keine.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Der Verlag erkl\u00e4rt, dass die inhaltliche Qualit\u00e4t des Beitrags durch zwei unabh\u00e4ngige Gutachten best\u00e4tigt wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere f\u00fcr Pr\u00e4parate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}